Summit Therapeutics Relocates Principal Executive Offices
Ticker: SMMT · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, administrative
TL;DR
Summit Therapeutics HQ moving from CA to FL. Big changes ahead?
AI Summary
On March 5, 2024, Summit Therapeutics Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices from Menlo Park, CA to Miami, FL. The new address is 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
Why It Matters
A change in principal executive offices can signal strategic shifts, operational adjustments, or potential cost-saving measures for the company.
Risk Assessment
Risk Level: low — This filing reports a change of address for executive offices, which is a routine administrative event with no immediate financial or operational risk.
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- March 5, 2024 (date) — Date of Report
- Menlo Park, CA (location) — Former Principal Executive Offices
- Miami, FL (location) — New Principal Executive Offices
- 601 Brickell Key Drive, Suite 1000, Miami, FL 33131 (address) — New Principal Executive Offices Address
FAQ
What is the new address for Summit Therapeutics Inc.'s principal executive offices?
The new address is 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
When was this change of address reported?
The change of address was reported on March 5, 2024.
What was the previous location of Summit Therapeutics Inc.'s principal executive offices?
The previous location was Menlo Park, CA.
Is this a change in the company's legal domicile?
No, the filing indicates the company is incorporated in Delaware and this is a change in principal executive offices, not the state of incorporation.
Does this filing indicate any specific operational changes or strategic shifts?
The filing itself only reports the change of address; it does not provide specific details on operational changes or strategic shifts.
Filing Stats: 464 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-03-05 16:05:09
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
Filing Documents
- smmt-20240305.htm (8-K) — 28KB
- a2024_prx0305xbarclayste.htm (EX-99.1) — 8KB
- a2024_prx0305xbarclayste001.jpg (GRAPHIC) — 251KB
- a2024_prx0305xbarclayste002.jpg (GRAPHIC) — 247KB
- 0001599298-24-000036.txt ( ) — 879KB
- smmt-20240305.xsd (EX-101.SCH) — 2KB
- smmt-20240305_def.xml (EX-101.DEF) — 14KB
- smmt-20240305_lab.xml (EX-101.LAB) — 28KB
- smmt-20240305_pre.xml (EX-101.PRE) — 15KB
- smmt-20240305_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On March 5, 2024, Summit Therapeutics, Inc. (the "Company") issued a press release announcing that it will participate in and present at Barclays 26th Annual Global Healthcare Conference, which will be held in Miami Beach, FL, from March 12-14, 2024. The Company will present on Tuesday March 12, 2024 at 2:35pm ET. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated March 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: March 5, 2024 By: /s/ Ankur Dhingra Chief Financial Officer (Principal Financial Officer)